Cagrilintide: A Laboratory Research Reference

Cagrilintide is a synthetic, long-acting peptide analogue of amylin. It is studied in laboratory research for its activity at calcitonin and amylin receptors and its influence on energy-balance signalling in experimental models.

This page is a non-promotional scientific reference for researchers. It summarises the chemical identity, molecular characteristics, mechanism as described in the literature, research areas, and analytical testing of cagrilintide. It does not provide dosing, therapeutic, or human-use guidance of any kind. Cagrilintide supplied by Bulk Aussie Peptides is for laboratory research purposes only.

What Is Cagrilintide?

Cagrilintide is a synthetic analogue of amylin, a peptide hormone that co-secretes with insulin and participates in the regulation of feeding and glucose metabolism. Cagrilintide is engineered for a long duration of action, allowing sustained investigation of amylin-receptor activity in research models. Its design parallels that of other long-acting incretin-family analogues used in metabolic research.

For background on how synthetic research peptides are produced and verified, see the synthetic peptides research guide.

Molecular Characteristics

Several molecular properties are used to identify cagrilintide in analytical documentation:

• Classification: a synthetic, long-acting amylin analogue that engages calcitonin and amylin receptors.
• Modification: engineered for extended circulating duration relative to native amylin through stabilising design features.
• Molecular weight: reported in Daltons (Da) on product documentation; the measured value on a Certificate of Analysis should be compared against the theoretical mass derived from the sequence.
• Physical form: supplied as a lyophilised (freeze-dried) powder, the standard presentation for research peptides.

How Cagrilintide Works

Cagrilintide exerts its studied effects through binding to and activation of receptors for the calcitonin/amylin family. In laboratory models, engagement of these receptors is associated with signalling that influences energy balance, food intake, and glucose handling. Structural studies describe cagrilintide interacting with components of the calcitonin and amylin receptor complexes.

These observations describe receptor pharmacology in model systems and are preclinical; they do not constitute a therapeutic use.

Areas of Scientific Research

The research literature describes several lines of investigation involving cagrilintide:

• Amylin/calcitonin receptor pharmacology: characterisation of receptor binding and signal transduction.
• Energy-balance signalling: studies of appetite and body-weight regulation in experimental metabolic models.
• Combination studies: investigation of co-agonism with GLP-1 receptor agonists in preclinical research.

These investigations are conducted in vitro or in approved animal research models under institutional oversight. They do not translate to approved human use.

Analytical Testing

As with other research peptides, cagrilintide is characterised using:

• HPLC for purity assessment, reported as a percentage of total peak area.
• Mass spectrometry for identity confirmation, by comparing measured molecular mass to the theoretical value.

Guidance on interpreting the resulting documents is available in the article on how to read a peptide Certificate of Analysis.

Storage and Handling

In a laboratory context, lyophilised cagrilintide is typically stored in a freezer, protected from light and moisture, and handled according to the product-specific documentation. Once reconstituted, the resulting solution is refrigerated and used within the timeframe stated in the documentation. General guidance is covered in the peptide storage and stability reference.

Frequently Asked Questions

• What is cagrilintide? Cagrilintide is a synthetic, long-acting analogue of the peptide hormone amylin.
• What receptors does cagrilintide target? It engages calcitonin and amylin receptors.
• What is cagrilintide studied for? It is investigated in laboratory models for amylin-receptor pharmacology and energy-balance signalling.
• Is cagrilintide an incretin? It is related to but distinct from GLP-1 agonists; it is an amylin analogue, though it is frequently studied alongside incretin peptides.
• How is cagrilintide purity tested? Purity is commonly estimated by HPLC, while identity is confirmed by mass spectrometry.

References

• Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., et al. (2021). Development of cagrilintide, a long-acting amylin analogue. Journal of Medicinal Chemistry, 64(15), 11183–11194. PubMed 34288673
• Lau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., et al. (2023). Once-weekly cagrilintide for weight management in people with overweight and obesity. The Lancet, 402(10412), 1619–1631. PubMed 36883831

Related Research Resources

• Semaglutide: A Laboratory Research Reference — a related GLP-1 metabolic peptide.
• Mazdutide: A Laboratory Research Reference — a dual GLP-1/glucagon agonist.
• Synthetic Peptides: Research Guide — how research peptides are produced and verified.